In the several years since Ozempic was approved by the FDA, there have been adverse event reports of Ozempic gastric side effects such as gastroparesis, stomach paralysis, and intestinal blockage cases in patients using Ozempic. Gastroparesis may also be called delayed gastric emptying. Gastroparesis is a long-term, chronic condition that can be … [Read more...]
Syfovre Eye Injections Adverse Reactions Update August 2023
We have some new information about Syfovre eye injections adverse reactions causing vision loss and blindness from Apellis Pharmaceuticals and the American Society of Retina Specialists (ASRS). Apellis Pharmaceuticals said that it has confirmed seven cases of Syfovre eye injections adverse reactions. More specifically, these Syfovre vision loss … [Read more...]
Tepezza-Related Hearing Problems Warning July 2023
A warning about the risks of Tepezza-related hearing problems was finally added with a Tepezza drug label change in July 2023. Some of the various hearing problems associated with Tepezza can cause hearing loss and can be permanent. In more detail, in the current Tepezza Full Prescribing Information (Revised: July 2023) document, we point out … [Read more...]
Syfovre-related Vision Loss Reported In Patients After Their First Injection
Syfovre-related vision loss has been reported in patients after the first time they used a Syfovre injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In mid-July 2023 the American Society of Retinal Specialists (ASRS) issued a warning letter about Syfovre-related vision loss as well as some other … [Read more...]
Syfovre Retinal Vasculitis Cases Warning Letter July 2023
The American Society of Retinal Specialists (ASRS) issued a warning letter about the Syfovre retinal vasculitis cases in patients who used this injection eye drug. Syfovre is a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Occlusive retinal vasculitis is a type of eye inflammation that blocks blood flow … [Read more...]
Ozempic Safety Issues Update: July 2023 Edition
In this Ozempic safety issues update we report on thyroid cancer, gallbladder disease, and suicidal thoughts as being possible Ozempic side effects. The European Medicines Agency (EMA) recently announced it has begun an investigation into Ozempic and suicidal thoughts as well as self-harm. From July 11, 2023 document “EMA statement on ongoing … [Read more...]
Ozempic Gallbladder Cases: Gallbladder Disease and Gallbladder Removal
The use of Ozempic has been associated with gallbladder diseases such as gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis). These Ozempic side effects can lead to gallbladder removal surgery (cholecystectomy). We are currently investigating certain Ozempic gallbladder cases as possible Ozempic drug injury lawsuits that … [Read more...]
Trulicity Double-Dose Recall in 2021 is Still a Drug Safety Issue in 2023
There was a relatively “low profile” Trulicity double-dose recall by Eli Lilly & Company back in 2021. Because there may still be thousands of double-dose Trulicity injectors in patients’ homes, we are concerned that this is an ongoing Trulicity drug safety issue. Here are seven reasons why: Some Trulicity autoinjector devices labeled as … [Read more...]
Prolia Side Effect: Hypocalcemia in Patients on Dialysis
This relatively new Prolia side effect, hypocalcemia, first came to our attention in late 2022 with the release of this November 22, 2022 document, “FDA Drug Safety Communication: FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)”. From that November 2022 FDA Drug Safety … [Read more...]
EzriCare Artificial Tears Case Reports Involving Vision Loss
A recent edition of the JAMA Ophthalmology medical journal presented two EzriCare Artificial Tears case reports about serious infection and vision loss associated with these over-the-counter (OTC) eye drops from Global Pharma. The two EzriCare Artificial Tears case reports are set forth in these March 2023 JAMA Ophthalmology medical journal … [Read more...]